Main Article Content
Background: In December 2019, an episode of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV2) was reported in Wuhan, China and has spread around the world, increasing the number of contagions. Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are common herpesviruses that can cause persistent latent infections and affect the developing immune system.The study was conducted to explore the prevalence and reactivation of CMV and EBV antibodies in COVID-19 patients group in comparison to healthy group and to investigate the association between the presence of these viruses with each of severity of disease and oral hygiene. Materials and Methods: Eighty Five subjects were participated in this case control study (50 patients with COVID-19 and 35 healthy controls), their age range from 18 to 77 years. Oral health status was established by oral hygiene index. Serum obtained from patients and controls was analyzed using ELISA to assess levels of anti- CMV and anti- EBV antibodies. Results: The study revealed that the mean of anti-EBV IgG in patients was significantly elevated (p<0.01) than that in controls. Otherwise, there was no significant difference (p>0.05) in levels of anti- EBV IgM, anti- CMV IgG and IgM between two groups (P>0.05). In addition there were no significant differences between patients and controls (p>0.05) in the number and percentage of anti-EBV and anti-CMV antibodies. Interestingly, there was a significant increase in the level of anti-CMV IgM in severe cases as compared to mild cases, (P<0.01). Furthermore, these results revealed that there were no significant differences (P>0.05) in levels of anti-viral antibodies in patients with good oral hygiene compared to patients with poor oral hygiene. Conclusions: Higher frequency of anti-EBV IgG among patients indicates that latent infection is more common in COVID-19 patients. While an increased percentage of anti-CMV IgM indicated reactivation of latent infection and is related to disease severity suggesting that COVID-19 can cause cellular immune impairment.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licenses and Copyright
The following policy applies in The Journal of Baghdad College of Dentistry (JBCD):
# JBCD applies the Creative Commons Attribution (CC BY) license to articles and other works we publish. If you submit your paper for publication by JBCD, you agree to have the CC BY license applied to your work. Under this Open Access license, you as the author agree that anyone can reuse your article in whole or part for any purpose, for free, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and original source are properly cited. This facilitates freedom in re-use and also ensures that JBCD content can be mined without barriers for the needs of research.
# If your manuscript contains content such as photos, images, figures, tables, audio files, videos, etc., that you or your co-authors do not own, we will require you to provide us with proof that the owner of that content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. We provide a form you can use to ask for and obtain permission from the owner. If you do not have owner permission, we will ask you to remove that content and/or replace it with other content that you own or have such permission to use.Don't assume that you can use any content you find on the Internet, or that the content is fair game just because it isn't clear who the owner is or what license applies.
# Many authors assume that if they previously published a paper through another publisher, they own the rights to that content and they can freely use that content in their paper, but thatâ€™s not necessarily the case, it depends on the license that covers the other paper. Some publishers allow free and unrestricted re-use of article content they own, such as under the CC BY license. Other publishers use licenses that allow re-use only if the same license is applied by the person or publisher re-using the content. If the paper was published under a CC BY license or another license that allows free and unrestricted use, you may use the content in your JBCD paper provided that you give proper attribution, as explained above.If the content was published under a more restrictive license, you must ascertain what rights you have under that license. At a minimum, review the license to make sure you can use the content. Contact that JBCD if you have any questions about the license. If the license does not permit you to use the content in a paper that will be covered by an unrestricted license, you must obtain written permission from the publisher to use the content in your JBCD paper. Please do not include any content in your JBCD paper which you do not have rights to use, and always give proper attribution.
# If any relevant accompanying data is submitted to repositories with stated licensing policies, the policies should not be more restrictive than CC BY.
# JBCD reserves the right to remove any photos, captures, images, figures, tables, illustrations, audio and video files, and the like, from any paper, whether before or after publication, if we have reason to believe that the content was included in your paper without permission from the owner of the content.